Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019964 | Mood Disorders NIH | 0.71 |
| D004194 | Disease NIH | 0.16 |
| D001008 | Anxiety Disorders NIH | 0.14 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The response to COVID-19 means social isolation/distancing for the majority of the UK. This has the potential to negatively affect all domains of quality of life (QoL). QoL can be improved by giving feedback on gaps between someone's perceived QoL in a domain and how important it is to them (plus prompting reflective questions). However, interventions that are designed to improve QoL may increase the effectiveness of this as optimised behaviour change techniques can be used. This study aims to develop and test a quality of life intervention during social isolation/distancing.
Description: Measure of quality of life, score ranges from 0-100 per domain, with a higher score indicating greater quality of life
Measure: Change in World Health Organisation Quality of Life Combination Time: Change from baseline quality of life to 2 weeks post interventionDescription: Measure of quality of life, score ranges from 0-100 per domain, with a higher score
Measure: Change in World Health Organisation Quality of Life Combination Time: Change from baseline quality of life to 3 months post interventionDescription: Measure of quality of life, score ranges from 0-100 per domain, with a higher score
Measure: Change in World Health Organisation Quality of Life Combination Time: Change from baseline quality of life to 6 months post interventionDescription: Measure of social isolation, score ranges between 0 and 30, with a higher score indicating more social engagement.
Measure: Change in The Lubben Social Network Scale Time: Change from baseline social isolation to 2 weeks post interventionDescription: Measure of social isolation, score ranges between 0 and 30, with a higher score indicating more social engagement.
Measure: Change in The Lubben Social Network Scale Time: Change from baseline social isolation to 3 months post interventionDescription: Measure of social isolation, score ranges between 0 and 30, with a higher score indicating more social engagement.
Measure: Change in The Lubben Social Network Scale Time: Change from baseline social isolation to 6 months post interventionDescription: Measure of loneliness, score ranges between 0 and 50, with a higher score indicating less loneliness.
Measure: Change in 6-Item Loneliness Scale Time: Change from baseline loneliness to 2 weeks post interventionDescription: Measure of loneliness, score ranges between 0 and 50, with a higher score indicating less loneliness.
Measure: Change in 6-Item Loneliness Scale Time: Change from baseline loneliness to 3 months post interventionDescription: Measure of loneliness, score ranges between 0 and 50, with a higher score indicating less loneliness.
Measure: Change in 6-Item Loneliness Scale Time: Change from baseline loneliness to 6 months post interventionDescription: Measure of importance of different facets of quality of life, score ranges 0-200, with a higher score indicating greater importance of quality of life.
Measure: Quality of Life Importance Ratings Time: Change from baseline importance to 2 weeks post interventionDescription: Measure of importance of different facets of quality of life, score ranges 0-200, with a higher score indicating greater importance of quality of life.
Measure: Quality of Life Importance Ratings Time: Change from baseline importance to 3 months post interventionDescription: Measure of importance of different facets of quality of life, score ranges 0-200, with a higher score indicating greater importance of quality of life.
Measure: Quality of Life Importance Ratings Time: Change from baseline importance to 6 months post interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports